<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en" article-type="review-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id>
      <journal-title>Pharmaceuticals</journal-title>
      <abbrev-journal-title abbrev-type="publisher">Pharmaceuticals</abbrev-journal-title>
      <abbrev-journal-title abbrev-type="pubmed">Pharmaceuticals</abbrev-journal-title>
      <issn pub-type="epub">1424-8247</issn>
      <publisher>
        <publisher-name>MDPI</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3390/ph5030317</article-id>
      <article-id pub-id-type="publisher-id">pharmaceuticals-05-00317</article-id>
      <article-categories>
        <subj-group>
          <subject>Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Pyrazole Carbohydrazide Derivatives of Pharmaceutical Interest</article-title>
      </title-group>
     
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Dias</surname>
            <given-names>Luiza Rosaria Sousa</given-names>
          </name>
          <xref rid="c1-pharmaceuticals-05-00317" ref-type="corresp">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Salvador</surname>
            <given-names>Raquel Rocha Silva</given-names>
          </name>
        </contrib>
      </contrib-group>
       <aff id="af1-pharmaceuticals-05-00317">Laboratório de Química Medicinal (LQMed), Faculdade de Farmácia, Universidade Federal Fluminense (UFF), Rua Mário Viana, 523, Santa Rosa, Niterói 24241-000, RJ, Brazil</aff>
      <author-notes>
        <corresp id="c1-pharmaceuticals-05-00317"><label>*</label> Author  to whom correspondence should be addressed; Email: <email>ldias@vm.uff.br</email>; Tel.: +55-21-2629-9588; Fax: +55-21-2629-9578.</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>16</day>
        <month>03</month>
        <year>2012</year>
      </pub-date>
      <pub-date pub-type="collection"><month>03</month>
        <year>2012</year>
      </pub-date>
      <volume>5</volume>
      <issue>3</issue>
      <fpage>317</fpage>
      <lpage>324</lpage>
      <history>
        <date date-type="received">
          <day>06</day>
          <month>02</month>
          <year>2012</year>
        </date>
        <date date-type="rev-recd">
          <day>09</day>
          <month>03</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>12</day>
          <month>03</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>©  2012 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement>
        <copyright-year>2012</copyright-year>
        <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/">
          <p>This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).</p>
        </license>
      </permissions>
      <abstract>
        <p>The main purpose of this paper is to provide an insight into the biological activities of pyrazole derivatives which contain the carbohydrazide moiety.</p>
      </abstract>
      <kwd-group>
        <kwd>pyrazole</kwd>
        <kwd>carbohydrazide</kwd>
        <kwd>biological activity</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>1. Introduction</title>
      <p>Clinically biological activity is the result of a chemical compound’s interaction with a human organism. The biological activity is dependent upon the compound’s structure and its physical-chemical characteristics, as well as the biological entity and its mode of therapeutic treatment. Nonetheless, many times chemical compounds reveal a spectrum of different types of biological activity. Some of them are useful in the treatment of definite diseases, where others may cause various side and toxic effects. This complex of activities caused by the chemical compound in biological entities is called the “biological activity spectrum of the substance”.</p>
      <p>Hydrazides, carbohydrazides and similar compounds are well known as useful building blocks for the synthesis of a variety of heterocyclic rings. A large number of heterocyclic carbohydrazides and their derivatives are reported to exhibit significant biological activities [<xref ref-type="bibr" rid="B1-pharmaceuticals-05-00317">1</xref>,<xref ref-type="bibr" rid="B2-pharmaceuticals-05-00317">2</xref>] and the carbohydrazide function represents an important pharmacophoric group in several classes of therapeutically useful substances [<xref ref-type="bibr" rid="B1-pharmaceuticals-05-00317">1</xref>,<xref ref-type="bibr" rid="B3-pharmaceuticals-05-00317">3</xref>,<xref ref-type="bibr" rid="B4-pharmaceuticals-05-00317">4</xref>,<xref ref-type="bibr" rid="B5-pharmaceuticals-05-00317">5</xref>,<xref ref-type="bibr" rid="B6-pharmaceuticals-05-00317">6</xref>,<xref ref-type="bibr" rid="B7-pharmaceuticals-05-00317">7</xref>,<xref ref-type="bibr" rid="B8-pharmaceuticals-05-00317">8</xref>]. In this paper, the authors will discuss the biological activity spectrum of various pyrazole derivatives containing carbohydrazide moieties.</p>
    </sec>
    <sec>
      <title>2. Pyrazole Compounds with Carbohydrazide Moiety Internalized</title>
      <p>The core pyrazole structure in general has attracted widespread attention because of the diversity of biological activity shown by derivatives of this nucleus. In fact, one of the first synthetic organic compounds to find use as an important drug was a pyrazolone. Antipyrine (<bold>1</bold>), first prepared in 1887, was used as antipyretic, analgesic and anti-inflammatory. Modifications in the pyrazolone nucleus led to the discovery of dipyrone (<bold>2</bold>), an analgesic and antipyretic drug, still used in several countries in Central and South America as well as in Europe, Asia, and Africa.</p>
      <p>Pyrazolone derivatives are still under investigation [<xref ref-type="bibr" rid="B9-pharmaceuticals-05-00317">9</xref>,<xref ref-type="bibr" rid="B10-pharmaceuticals-05-00317">10</xref>]. In this way, there are some derivatives with a broad spectrum of activities, including antidepressant and anti-inflammatory effects. 2-{2-[4-(4-Fluorobenzylidene)-2-(4-fluorophenyl)-5-oxo-4,5-dihydroimidazol-1-yl)acetyl}-3-methyl-2,4-dihydro-1<italic>H</italic>-pyrazole-5-one (<bold>3</bold>) is an effective anti-inflammatory agent in the carrageenan induced rat paw edema test [<xref ref-type="bibr" rid="B10-pharmaceuticals-05-00317">10</xref>] and ethyl 1-(thiophene-2-carbonyl)-4-cyano-5-oxo-2,5-dihydro-1<italic>H</italic>-pyrazole-3-carboxylate (<bold>4</bold>) showed good antidepressant activity [<xref ref-type="bibr" rid="B9-pharmaceuticals-05-00317">9</xref>]. Interesting, the carbohydrazide moiety can be observed internalized into the heterocyclic nucleus at the core structure of pyrazolones (<xref ref-type="fig" rid="pharmaceuticals-05-00317-f001">Figure 1</xref>).</p>
      <fig id="pharmaceuticals-05-00317-f001" position="anchor">
        <label>Figure 1</label>
        <caption>
          <p>Some pyrazolone derivatives that present biological activities. Antipyretic and analgesic activities could be observed for the derivatives <bold>1</bold> and <bold>2</bold>, anti-inflammatory activity could be observed for the derivatives <bold>1</bold> and <bold>3</bold> and the derivative <bold>4</bold> presents antidepressant activity. In the core pyrazolones we can observe the internalized carbohydrazide functions (<bold>A</bold>).</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-05-00317-g001.tif"/>
      </fig>
      <p>In this way some 1-<italic>H</italic>-pyrazole and 2,3-dihydro-1-<italic>H</italic>-pyrazole derivatives that have the internalized carbohydrazide moiety also exhibit interesting biological activities (<xref ref-type="fig" rid="pharmaceuticals-05-00317-f002">Figure 2</xref>). Antimicrobial activity could be observed for the 1<italic>H</italic>-indole-2yl group (compounds <bold>6</bold>–<bold>8</bold>) with moieties such as 4-methylthiophene-3-yl (compound <bold>5</bold>) and 1-(naphtho[2,1-<italic>b</italic>]furan-2-yl) (compound <bold>10</bold>) connected to the carbonyl group of the carbohydrazide function [<xref ref-type="bibr" rid="B6-pharmaceuticals-05-00317">6</xref>,<xref ref-type="bibr" rid="B11-pharmaceuticals-05-00317">11</xref>,<xref ref-type="bibr" rid="B12-pharmaceuticals-05-00317">12</xref>]. The derivative <bold>5</bold> also exhibited analgesic activity [<xref ref-type="bibr" rid="B11-pharmaceuticals-05-00317">11</xref>]. Only the derivative <bold>9</bold> presented anti-inflammatory activity in the carrageenan induced rat paw edema assay [<xref ref-type="bibr" rid="B10-pharmaceuticals-05-00317">10</xref>].</p>
      <fig id="pharmaceuticals-05-00317-f002" position="anchor">
        <label>Figure 2</label>
        <caption>
          <p>1-<italic>H</italic>-pyrazole derivatives <bold>5</bold>–<bold>9</bold> and 2,3-dihydro-1-<italic>H</italic>-pyrazole derivative <bold>10</bold> that exhibit biological activities. An internalized carbohydrazide function (<bold>A</bold>) can be observed.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-05-00317-g002.tif"/>
      </fig>
    </sec>
    <sec>
      <title>3. Biological Activities of Carbohydrazides Derived from Pyrazole</title>
      <p>An investigation of the relationship between the pyrazole nucleus and the position of carbohydrazide moiety substituent with biological activity was one of the goals of this study. Substitution with carbohydrazide moiety at position C-3 of the pyrazole ring (<xref ref-type="fig" rid="pharmaceuticals-05-00317-f003">Figure 3</xref>) seems to provide derivatives that exhibit biological activities such as antitumor (compounds <bold>11</bold>–<bold>13</bold>) and cannabinoid antagonist (compound <bold>14</bold>) [<xref ref-type="bibr" rid="B13-pharmaceuticals-05-00317">13</xref>,<xref ref-type="bibr" rid="B14-pharmaceuticals-05-00317">14</xref>,<xref ref-type="bibr" rid="B15-pharmaceuticals-05-00317">15</xref>,<xref ref-type="bibr" rid="B16-pharmaceuticals-05-00317">16</xref>].</p>
      <fig id="pharmaceuticals-05-00317-f003" position="anchor">
        <label>Figure 3</label>
        <caption>
          <p>Derivatives that exhibit antitumor activity: 1-<italic>H</italic>-pyrazole-3-carbohydrazide derivatives (<bold>11</bold>, R<sub>1</sub> = phenyl), 4-hydroxypyrazole derivatives (<bold>12</bold> and <bold>13</bold>, R<sub>1</sub> = 4-chlorophenyl, R<sub>2</sub> = H), 1-<italic>H</italic>-pyrazole-5-carbohydrazide derivatives (<bold>15</bold>, R<sub>1</sub> = 4-<italic>substituted</italic>-benzyl or -C(O)CH<sub>2</sub>-O-phenyl, R<sub>2</sub> = 4-<italic>substituted</italic>-benzyl or 4-<italic>substituted</italic>-phenyl) and (<bold>16</bold>, R<sub>1</sub>, R<sub>2</sub> = benzyl or 4-<italic>substituted</italic>-benzyl). The compounds <bold>12</bold> and <bold>13</bold> have the carbohydrazide function (<bold>A</bold>) internalized into a heterocyclic nucleus.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-05-00317-g003.tif"/>
      </fig>
      <p><italic>N</italic>-(Piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1<italic>H</italic>-pyrazole-3-carbohydrazide (<bold>14</bold>, rimonabant, SR141716, <xref ref-type="fig" rid="pharmaceuticals-05-00317-f004">Figure 4</xref>) is a potent CB1 cannabinoid receptor antagonist. This activity can be investigated to provide a chemical tool for further characterization of the cannabinoid pharmacophore and its relationship to the binding domain of cannabinoid antagonists [<xref ref-type="bibr" rid="B15-pharmaceuticals-05-00317">15</xref>,<xref ref-type="bibr" rid="B16-pharmaceuticals-05-00317">16</xref>]. Its main effect is reduction in appetite [<xref ref-type="bibr" rid="B17-pharmaceuticals-05-00317">17</xref>,<xref ref-type="bibr" rid="B18-pharmaceuticals-05-00317">18</xref>]. </p>
      <fig id="pharmaceuticals-05-00317-f004" position="anchor">
        <label>Figure 4</label>
        <caption>
          <p>Rimonabant (SR141716, <bold>14</bold>). </p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-05-00317-g004.tif"/>
      </fig>
      <p>The anticancer activity of the 4-hydroxypyrazole compounds <bold>12</bold> and <bold>13</bold> was revealed by the broad spectrum of antitumor potential against tumor cell lines at the GI50 and TGI levels, together with a mild cytotoxic activity [<xref ref-type="bibr" rid="B14-pharmaceuticals-05-00317">14</xref>]. The 1-phenylindeno[1,2-<italic>c</italic>]pyrazole <bold>11</bold> also showed potent cytotoxic activity [<xref ref-type="bibr" rid="B13-pharmaceuticals-05-00317">13</xref>].</p>
      <p>Substitution with a carbohydrazide moiety at position C-5 of the pyrazole ring seems to provide derivatives that exhibit antitumor activity too (compounds <bold>15</bold> and <bold>16</bold>, <xref ref-type="fig" rid="pharmaceuticals-05-00317-f003">Figure 3</xref>), beyond fungicidal and herbicidal activities [<xref ref-type="bibr" rid="B8-pharmaceuticals-05-00317">8</xref>,<xref ref-type="bibr" rid="B19-pharmaceuticals-05-00317">19</xref>,<xref ref-type="bibr" rid="B20-pharmaceuticals-05-00317">20</xref>,<xref ref-type="bibr" rid="B21-pharmaceuticals-05-00317">21</xref>,<xref ref-type="bibr" rid="B22-pharmaceuticals-05-00317">22</xref>,<xref ref-type="bibr" rid="B23-pharmaceuticals-05-00317">23</xref>,<xref ref-type="bibr" rid="B24-pharmaceuticals-05-00317">24</xref>].</p>
      <p>The research for novel targeted therapies that can induce death in cancer cells or sensitize them to cytotoxic agents involves some 1<italic>H</italic>-pyrazole-5-carbohydrazide derivatives that can inhibit the growth of A549 cells in dosage-dependent and time-dependent manners [<xref ref-type="bibr" rid="B19-pharmaceuticals-05-00317">19</xref>,<xref ref-type="bibr" rid="B20-pharmaceuticals-05-00317">20</xref>]. Salicylaldehyde-pyrazole-carbohydrazide derivatives (compound <bold>16</bold>, <xref ref-type="fig" rid="pharmaceuticals-05-00317-f003">Figure 3</xref>) have been investigated in inhibition of the proliferation of A549 lung cancer cells [<xref ref-type="bibr" rid="B8-pharmaceuticals-05-00317">8</xref>,<xref ref-type="bibr" rid="B21-pharmaceuticals-05-00317">21</xref>,<xref ref-type="bibr" rid="B22-pharmaceuticals-05-00317">22</xref>,<xref ref-type="bibr" rid="B25-pharmaceuticals-05-00317">25</xref>,<xref ref-type="bibr" rid="B26-pharmaceuticals-05-00317">26</xref>]. In light of the increased anticancer activities of some copper complexes, salicylaldehyde-pyrazole-carbohydrazide derivatives shown to be potent growth inhibitors to A549 cells via inducing apoptosis [<xref ref-type="bibr" rid="B22-pharmaceuticals-05-00317">22</xref>]. </p>
      <p>On the other hand, substitution with a carbohydrazide moiety at position C-4 of the pyrazole ring seems to provide derivatives that exhibit different biological activities such as antinociceptive, antibacterial and antiparasital activities.</p>
      <p>The 4-dimethylaminephenyl derivative of 1<italic>H</italic>-pyrazole-4-carbohydrazide, (<bold>17</bold>, ED<sub>50</sub> 1.41 mg/Kg) showed an antinociceptive activity eleven times more potent than dipyrone (ED<sub>50</sub> 15.8 mg/Kg) [<xref ref-type="bibr" rid="B27-pharmaceuticals-05-00317">27</xref>,<xref ref-type="bibr" rid="B28-pharmaceuticals-05-00317">28</xref>]. However, the 4-hydroxyphenyl derivative <bold>18</bold> showed potential antimalarial activity targeting the inhibition of <italic>Plasmodium falciparum</italic> cysteine protease [<xref ref-type="bibr" rid="B29-pharmaceuticals-05-00317">29</xref>].</p>
      <p>Some 1<italic>H</italic>-pyrazole-4-carbohydrazide derivatives have provided new perspectives on the development of drugs with activities against microbial diseases. Apparently, the carbohydrazide moiety and the nature of the substituents introduced in the <italic>N</italic>-phenyl ring (R<sub>1</sub> and R<sub>2</sub>) are crucial to determine the potentiality of the antimicrobial activity profile. A series of 1-(4-<italic>substituted</italic>-phenyl)-1<italic>H</italic>-pyrazole-4-carboxylic acid (4-<italic>substituted</italic>-benzilidene)-hydrazide derivatives (<bold>19</bold>) marked leishmanicidal activity on <italic>L. amazonensis</italic> [<xref ref-type="bibr" rid="B30-pharmaceuticals-05-00317">30</xref>,<xref ref-type="bibr" rid="B31-pharmaceuticals-05-00317">31</xref>]. Another series of 1<italic>H</italic>-pyrazole-4-carbohydrazides <bold>20</bold> presented moderate bactericidal and bacteriostatic properties [<xref ref-type="bibr" rid="B32-pharmaceuticals-05-00317">32</xref>].</p>
      <p>The insertion of a spacer unit (ethylenic moiety) between the aromatic subunit (<bold>R</bold>) and carbohydrazide function (<xref ref-type="fig" rid="pharmaceuticals-05-00317-f005">Figure 5</xref>) increases the distance from the aromatic units (<bold>R</bold> and <bold>R'</bold>) that were previously separated only by the carbohydrazide moiety. A phenyl aromatic ring with different substituents inserted into the ethylenic portion increased the lipophilicity and changed the stereoelectronic factors of these derivatives. These compounds presented trypanocidal activity, especially the compound <bold>21</bold> that was shown to be the most potent and to have the lowest toxicity from this series [<xref ref-type="bibr" rid="B33-pharmaceuticals-05-00317">33</xref>]. The reversal of position of the aromatic units (<bold>R</bold> and <bold>R'</bold>) as in derivative <bold>22</bold> exhibited anticonvulsant effects when evaluated by the standard pentylenetetrazole test and maximum electroshock seizure models [<xref ref-type="bibr" rid="B34-pharmaceuticals-05-00317">34</xref>].</p>
      <fig id="pharmaceuticals-05-00317-f005" position="anchor">
        <label>Figure 5</label>
        <caption>
          <p>1-<italic>H</italic>-pyrazole-4-carbohydrazide derivatives which show antimicrobial activity (compounds <bold>18</bold>–<bold>21</bold>) and anticonvulsant activity (compound <bold>22</bold>).</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-05-00317-g005.tif"/>
      </fig>
    </sec>
    <sec sec-type="conclusions">
      <title>4. Conclusions</title>
      <p>The biological activity of the various pyrazole derivatives containing carbohydrazide moieties discussed in this paper includes antidepressant, anticonvulsant, analgesic, anti-inflammatory, anticancer, antimicrobial, antinociceptive, and antiparasitic activity, such as, antimalarial, trypanocidal, and leishmanicidal. Even though they have a high significance in the pharmaceutical and biotechnological field with a wide spectrum of biological activities for their various derivatives, one must highlight that the carbohydrazide pyrazole chemical class could possess other biological profiles as they are found in many pharmaceutical lead molecules.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgements</title>
      <p>We thank Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ-Brazil), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq-Brazil) and Pró-Reitoria de Pesquisa, Pós-graduação e Inovação (PROPPi-UFF) for supporting this research.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="B1-pharmaceuticals-05-00317">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mansour</surname>
              <given-names>A.K.</given-names>
            </name>
            <name>
              <surname>Eid</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Khalil</surname>
              <given-names>N.S.A.M.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and reactions of some new heterocyclic carbohydrazides and related compounds as potential anticancer agents</article-title>
          <source>Molecules</source>
          <year>2003</year>
          <volume>8</volume>
          <fpage>744</fpage>
          <lpage>755</lpage>
          <pub-id pub-id-type="doi">10.3390/81000744</pub-id>
        </citation>
      </ref>
      <ref id="B2-pharmaceuticals-05-00317">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Metwally</surname>
              <given-names>K.A.</given-names>
            </name>
            <name>
              <surname>Abdel-Aziz</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Lashine</surname>
              <given-names>E.-S.M.</given-names>
            </name>
            <name>
              <surname>Husseiny</surname>
              <given-names>M.I.</given-names>
            </name>
            <name>
              <surname>Badawy</surname>
              <given-names>R.H.</given-names>
            </name>
          </person-group>
          <article-title>Hydrazones of 2-aryl-quinoline-4-carboxylic acid hydrazides: Synthesis and preliminary evaluation as antimicrobial agents</article-title>
          <source>Bioorg. Med. Chem.</source>
          <year>2006</year>
          <volume>14</volume>
          <fpage>8675</fpage>
          <lpage>8682</lpage>
        <pub-id pub-id-type="doi">10.1016/j.bmc.2006.08.022</pub-id><pub-id pub-id-type="pmid">16949294</pub-id></citation>
      </ref>
      <ref id="B3-pharmaceuticals-05-00317">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ghiglieri-Bertez</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Coquelet</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Alazet</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Bonne</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Dual inhibitors of the cyclooxygenase and lipoxygenase pathways: Synthesis and activity of hydrazone derivatives. [Inhibiteurs mixtes des voies de la cyclooxygénase et des lipoxygénases: Synthèse et activité de dérivés hydrazoniques]</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>1987</year>
          <volume>22</volume>
          <fpage>147</fpage>
          <lpage>152</lpage>
          <pub-id pub-id-type="doi">10.1016/0223-5234(87)90010-9</pub-id>
        </citation>
      </ref>
      <ref id="B4-pharmaceuticals-05-00317">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Combs</surname>
              <given-names>D.W.</given-names>
            </name>
            <name>
              <surname>Rampulla</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Demers</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>Falotico</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>J.B.</given-names>
            </name>
          </person-group>
          <article-title>Heteroatom analogues of bemoradan: Chemistry and cardiotonic activity of l,4-benzot hiazinylpyridazinones</article-title>
          <source>J. Med. Chem.</source>
          <year>1992</year>
          <volume>35</volume>
          <fpage>172</fpage>
          <lpage>176</lpage>
          <pub-id pub-id-type="doi">10.1021/jm00079a023</pub-id>
        </citation>
      </ref>
      <ref id="B5-pharmaceuticals-05-00317">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Montanari</surname>
              <given-names>M.L.C.</given-names>
            </name>
            <name>
              <surname>Montanari</surname>
              <given-names>C.A.</given-names>
            </name>
          </person-group>
          <article-title>Comparative QSAR of antimicrobial hydrazides. [Validação lateral em relações quantitativas entre estrutura e atividade farmacológica, QSAR.]</article-title>
          <source>Quím. Nova</source>
          <year>2002</year>
          <volume>25</volume>
          <fpage>231</fpage>
          <lpage>240</lpage>
          <pub-id pub-id-type="doi">10.1590/S0100-40422002000200011</pub-id>
        </citation>
      </ref>
      <ref id="B6-pharmaceuticals-05-00317">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Farghaly</surname>
              <given-names>A.R.A.H.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis, reactions and antimicrobial activity of some new indolyl-1,3,4-oxadiazole, triazole and pyrazole derivatives</article-title>
          <source>J. Chin. Chem. Soc.</source>
          <year>2004</year>
          <volume>51</volume>
          <fpage>147</fpage>
          <lpage>156</lpage>
        </citation>
      </ref>
      <ref id="B7-pharmaceuticals-05-00317">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sapijanskaite</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Mickevièius</surname>
              <given-names>V.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis of 1-(9-butylcarbazol-3-yl)-5-oxopyrrolidine-3-carboxylic acid derivatives</article-title>
          <source>Chem. Heterocycl. Compd.</source>
          <year>2008</year>
          <volume>44</volume>
          <fpage>807</fpage>
          <lpage>814</lpage>
        <pub-id pub-id-type="doi">10.1007/s10593-008-0113-6</pub-id></citation>
      </ref>
      <ref id="B8-pharmaceuticals-05-00317">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xia</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Fan</surname>
              <given-names>X.D.</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>B.X.</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Shin</surname>
              <given-names>D.S.</given-names>
            </name>
            <name>
              <surname>Miao</surname>
              <given-names>J.Y.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and structure activity relationships of novel 1-arylmethyl-3-aryl-1H-pyrazole-5-carbohydrazide hydrazone derivatives as potential agents against A549 lung cancer cells</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2008</year>
          <volume>43</volume>
          <fpage>2347</fpage>
          <lpage>2353</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejmech.2008.01.021</pub-id>
        </citation>
      </ref>
      <ref id="B9-pharmaceuticals-05-00317">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abdel-Aziz</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Abuo-Rahma</surname>
              <given-names>E.D.A.</given-names>
            </name>
            <name>
              <surname>Hassan</surname>
              <given-names>A.A.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis of novel pyrazole derivatives and evaluation of their antidepressant and anticonvulsant activities</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2009</year>
          <volume>44</volume>
          <fpage>3480</fpage>
          <lpage>3487</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejmech.2009.01.032</pub-id>
        </citation>
      </ref>
      <ref id="B10-pharmaceuticals-05-00317">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khalifa</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Abdelbaky</surname>
              <given-names>N.A.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis of new imidazolyl acetic acid derivatives with antiinflammatory and analgesic activities</article-title>
          <source>Arch. Pharm. Res.</source>
          <year>2008</year>
          <volume>31</volume>
          <fpage>419</fpage>
          <lpage>423</lpage>
          <pub-id pub-id-type="doi">10.1007/s12272-001-1173-x</pub-id>
        </citation>
      </ref>
      <ref id="B11-pharmaceuticals-05-00317">
        <label>11.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hafez</surname>
              <given-names>H.N.</given-names>
            </name>
            <name>
              <surname>El-Gazzara</surname>
              <given-names>A.B.A.</given-names>
            </name>
          </person-group>
          <article-title>Design and synthesis of 3-pyrazolyl-thiophene, thieno[2,3-d]pyrimidines as new bioactive and pharmacological activities</article-title>
          <source>Bioorg. Med. Chem. Lett.</source>
          <year>2008</year>
          <volume>18</volume>
          <fpage>5222</fpage>
          <lpage>5227</lpage>
        <pub-id pub-id-type="doi">10.1016/j.bmcl.2008.08.071</pub-id><pub-id pub-id-type="pmid">18783947</pub-id></citation>
      </ref>
      <ref id="B12-pharmaceuticals-05-00317">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kumaraswamy</surname>
              <given-names>M.N.</given-names>
            </name>
            <name>
              <surname>Chandrashekhar</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Shivakumar</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Mathias</surname>
              <given-names>D.A.P.</given-names>
            </name>
            <name>
              <surname>Mahadevan</surname>
              <given-names>K.M.</given-names>
            </name>
            <name>
              <surname>Vaidya</surname>
              <given-names>V.P.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and activity evaluation of 2-(1-naphtho[2,1-<italic>b</italic>]furan-2-yl-carbonyl)-3,5-disubstituted-2,3-dihydro-1H-pyrazoles</article-title>
          <source>Indian J. Pharm. Sci.</source>
          <year>2008</year>
          <volume>70</volume>
          <fpage>715</fpage>
          <lpage>720</lpage>
          <pub-id pub-id-type="doi">10.4103/0250-474X.49090</pub-id>
        </citation>
      </ref>
      <ref id="B13-pharmaceuticals-05-00317">
        <label>13.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hegazi</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Mohamed</surname>
              <given-names>H.A.</given-names>
            </name>
            <name>
              <surname>Dawood</surname>
              <given-names>K.M.</given-names>
            </name>
            <name>
              <surname>Badria</surname>
              <given-names>F.A.R.</given-names>
            </name>
          </person-group>
          <article-title>Cytotoxicity and utility of 1-indanone in the synthesis of some new heterocycles</article-title>
          <source>Chem. Pharm. Bull.</source>
          <year>2010</year>
          <volume>58</volume>
          <fpage>479</fpage>
          <lpage>483</lpage>
        <pub-id pub-id-type="doi">10.1248/cpb.58.479</pub-id><pub-id pub-id-type="pmid">20410628</pub-id></citation>
      </ref>
      <ref id="B14-pharmaceuticals-05-00317">
        <label>14.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rostom</surname>
              <given-names>S.A.F.</given-names>
            </name>
          </person-group>
          <article-title>Polysubstituted pyrazoles, part 6. Synthesis of some 1-(4-chlorophenyl)-4-hydroxy-1<italic>H</italic>-pyrazol-3-carbonyl derivatives linked to nitrogenous heterocyclic ring systems as potential antitumor agents</article-title>
          <source>Bioorg. Med. Chem.</source>
          <year>2010</year>
          <volume>18</volume>
          <fpage>2767</fpage>
          <lpage>2776</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bmc.2010.02.006</pub-id>
        </citation>
      </ref>
      <ref id="B15-pharmaceuticals-05-00317">
        <label>15.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Francisco</surname>
              <given-names>M.E.Y.</given-names>
            </name>
            <name>
              <surname>Seltzman</surname>
              <given-names>H.H.</given-names>
            </name>
            <name>
              <surname>Gilliam</surname>
              <given-names>A.F.</given-names>
            </name>
            <name>
              <surname>Mitchell</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Rider</surname>
              <given-names>S.L.</given-names>
            </name>
            <name>
              <surname>Pertwee</surname>
              <given-names>R.G.</given-names>
            </name>
            <name>
              <surname>Stevenson</surname>
              <given-names>L.A.</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>B.F.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and structure-activity relationships of amide and hydrazide analogues of the cannabinoid CB1 receptor antagonist <italic>N</italic>-(Piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1<italic>H</italic>-pyrazole-3-carboxamide (SR141716)</article-title>
          <source>J. Med. Chem.</source>
          <year>2002</year>
          <volume>45</volume>
          <fpage>2708</fpage>
          <lpage>2719</lpage>
          <pub-id pub-id-type="doi">10.1021/jm010498v</pub-id>
        </citation>
      </ref>
      <ref id="B16-pharmaceuticals-05-00317">
        <label>16.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Padgett</surname>
              <given-names>L.W.</given-names>
            </name>
          </person-group>
          <article-title>Recent developments in cannabinoid ligands</article-title>
          <source>Life Sci.</source>
          <year>2005</year>
          <volume>77</volume>
          <fpage>1767</fpage>
          <lpage>1798</lpage>
          <pub-id pub-id-type="doi">10.1016/j.lfs.2005.05.020</pub-id>
        </citation>
      </ref>
      <ref id="B17-pharmaceuticals-05-00317">
        <label>17.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fong</surname>
              <given-names>T.M.</given-names>
            </name>
            <name>
              <surname>Heymsfield</surname>
              <given-names>S.B.</given-names>
            </name>
          </person-group>
          <article-title>Cannabinoid-1 receptor inverse agonists: Current understanding of mechanism of action and unanswered questions CB1R mechanism of action</article-title>
          <source>Int. J. Obes.</source>
          <year>2009</year>
          <volume>33</volume>
          <fpage>947</fpage>
          <lpage>955</lpage>
          <pub-id pub-id-type="doi">10.1038/ijo.2009.132</pub-id>
        </citation>
      </ref>
      <ref id="B18-pharmaceuticals-05-00317">
        <label>18.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Soyka</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Koller</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Lesch</surname>
              <given-names>O.M.</given-names>
            </name>
            <name>
              <surname>Leweke</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Fehr</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Gann</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Mann</surname>
              <given-names>K.F.</given-names>
            </name>
           </person-group>
		  <collab>ACTOL Study Investigators</collab>
          <article-title>Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: Results from a placebo-controlled, double-blind trial</article-title>
          <source>J. Clin. Psychopharmacol.</source>
          <year>2008</year>
          <volume>28</volume>
          <fpage>317</fpage>
          <lpage>324</lpage>
          <pub-id pub-id-type="doi">10.1097/JCP.0b013e318172b8bc</pub-id>
        </citation>
      </ref>
      <ref id="B19-pharmaceuticals-05-00317">
        <label>19.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xia</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>Z.W.</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>B.X.</given-names>
            </name>
            <name>
              <surname>Ge</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Meng</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Shinc</surname>
              <given-names>D.S.</given-names>
            </name>
            <name>
              <surname>Miaob</surname>
              <given-names>J.Y.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and structure-activity relationships of novel 1-arylmethyl-3-aryl-1<italic>H</italic>-pyrazole-5-carbohydrazide derivatives as potential agents against A549 lung cancer cells</article-title>
          <source>Bioorg. Med. Chem.</source>
          <year>2007</year>
          <volume>15</volume>
          <fpage>6893</fpage>
          <lpage>6899</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bmc.2007.08.021</pub-id>
        </citation>
      </ref>
      <ref id="B20-pharmaceuticals-05-00317">
        <label>20.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fan</surname>
              <given-names>C.D.</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>B.X.</given-names>
            </name>
            <name>
              <surname>Wei</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>G.H.</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>W.L.</given-names>
            </name>
            <name>
              <surname>Miao</surname>
              <given-names>J.Y.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and discovery of autophagy inducers for A549 and H460 lung cancer cells, novel 1-(20-hydroxy-30-aroxypropyl)-3-aryl-1<italic>H</italic>-pyrazole-5-carbohydrazide derivatives</article-title>
          <source>Bioorg. Med. Chem. Lett.</source>
          <year>2008</year>
          <volume>18</volume>
          <fpage>3860</fpage>
          <lpage>3864</lpage>
        <pub-id pub-id-type="doi">10.1016/j.bmcl.2008.06.058</pub-id><pub-id pub-id-type="pmid">18595694</pub-id></citation>
      </ref>
      <ref id="B21-pharmaceuticals-05-00317">
        <label>21.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fan</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Miao</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Novel complex of copper and a salicylaldehyde pyrazole hydrazone derivative induces apoptosis through up-regulating integrin in vascular endothelial cells</article-title>
          <source>Chem Res. Toxicol.</source>
          <year>2009</year>
          <volume>22</volume>
          <fpage>1517</fpage>
          <lpage>1525</lpage>
        <pub-id pub-id-type="doi">10.1021/tx900111y</pub-id><pub-id pub-id-type="pmid">19621939</pub-id></citation>
      </ref>
      <ref id="B22-pharmaceuticals-05-00317">
        <label>22.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fan</surname>
              <given-names>C.D.</given-names>
            </name>
            <name>
              <surname>Su</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>B.X.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>S.L.</given-names>
            </name>
            <name>
              <surname>Miao</surname>
              <given-names>J.Y.</given-names>
            </name>
          </person-group>
          <article-title>A novel copper complex of salicylaldehyde pyrazole hydrazone induces apoptosis through up-regulating integrin b4 in H322 lung carcinoma cells</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2010</year>
          <volume>45</volume>
          <fpage>1438</fpage>
          <lpage>1446</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ejmech.2009.12.048</pub-id><pub-id pub-id-type="pmid">20089331</pub-id></citation>
      </ref>
      <ref id="B23-pharmaceuticals-05-00317">
        <label>23.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>Z.M.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>H.S.</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>W.G.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>X.S.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and biological activity of pyrazole derivatives</article-title>
          <source>Chem. J. Chin. Univ.</source>
          <year>1997</year>
          <volume>18</volume>
          <fpage>1794</fpage>
          <lpage>1799</lpage>
        </citation>
      </ref>
      <ref id="B24-pharmaceuticals-05-00317">
        <label>24.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>H.S.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Z.M.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis of some heteroaryl pyrazole derivatives and their biological activities</article-title>
          <source>Chin. J. Chem.</source>
          <year>2000</year>
          <volume>18</volume>
          <fpage>596</fpage>
          <lpage>602</lpage>
        </citation>
      </ref>
      <ref id="B25-pharmaceuticals-05-00317">
        <label>25.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lian</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Su</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>B.X.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>W.Y.</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>L.W.</given-names>
            </name>
            <name>
              <surname>Miao</surname>
              <given-names>J.Y.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and discovery of pyrazole-5-carbohydrazide <italic>N</italic>-glycosides as inducer of autophagy in A549 lung cancer cells</article-title>
          <source>Bioorg. Med. Chem.</source>
          <year>2009</year>
          <volume>17</volume>
          <fpage>7085</fpage>
          <lpage>7092</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bmc.2009.09.004</pub-id>
        </citation>
      </ref>
      <ref id="B26-pharmaceuticals-05-00317">
        <label>26.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zheng</surname>
              <given-names>L.W.</given-names>
            </name>
            <name>
              <surname>Wub</surname>
              <given-names>L.L.</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>B.X.</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>W.L.</given-names>
            </name>
            <name>
              <surname>Miao</surname>
              <given-names>J.Y.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis of novel substituted pyrazole-5-carbohydrazide hydrazone derivatives and discovery of a potent apoptosis inducer in A549 lung cancer cells</article-title>
          <source>Bioorg. Med. Chem.</source>
          <year>2009</year>
          <volume>17</volume>
          <fpage>1957</fpage>
          <lpage>1962</lpage>
        <pub-id pub-id-type="doi">10.1016/j.bmc.2009.01.037</pub-id><pub-id pub-id-type="pmid">19217789</pub-id></citation>
      </ref>
      <ref id="B27-pharmaceuticals-05-00317">
        <label>27.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Matheus</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>L.F.</given-names>
            </name>
            <name>
              <surname>Freitas</surname>
              <given-names>A.C.</given-names>
            </name>
            <name>
              <surname>Carvalho</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Barreiro</surname>
              <given-names>E.J.</given-names>
            </name>
          </person-group>
          <article-title>Antinociceptive property of new 4-acyl-arylhydrazone pyrazole compounds</article-title>
          <source>Braz. J. Med. Biol. Res.</source>
          <year>1991</year>
          <volume>24</volume>
          <fpage>1219</fpage>
          <lpage>1222</lpage>
        <pub-id pub-id-type="pmid">1843872</pub-id></citation>
      </ref>
      <ref id="B28-pharmaceuticals-05-00317">
        <label>28.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Matheus</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>L.F.</given-names>
            </name>
            <name>
              <surname>Freitas</surname>
              <given-names>A.C.C.</given-names>
            </name>
          </person-group>
          <article-title>Antinociceptive activity of new pyrazole derivatives</article-title>
          <source>Rev. Port. Farm.</source>
          <year>1998</year>
          <volume>XLVIII</volume>
          <fpage>153</fpage>
          <lpage>158</lpage>
        </citation>
      </ref>
      <ref id="B29-pharmaceuticals-05-00317">
        <label>29.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sant'anna</surname>
              <given-names>C.M.R.</given-names>
            </name>
            <name>
              <surname>Alencastro</surname>
              <given-names>R.B.</given-names>
            </name>
            <name>
              <surname>Rodrigues</surname>
              <given-names>C.R.</given-names>
            </name>
            <name>
              <surname>Barreiro</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Barreiro</surname>
              <given-names>E.J.</given-names>
            </name>
            <name>
              <surname>Motta Neto</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Freitas</surname>
              <given-names>A.C.C.</given-names>
            </name>
          </person-group>
          <article-title>A semiempirical study of pyrazole acylhydrazones as potential antimalarial agents</article-title>
          <source>Int. J. Quantum Chem.</source>
          <year>1996</year>
          <volume>60</volume>
          <fpage>1835</fpage>
          <lpage>1843</lpage>
          <pub-id pub-id-type="doi">10.1002/(SICI)1097-461X(1996)60:8&lt;1835::AID-QUA11&gt;3.0.CO;2-Z</pub-id>
        </citation>
      </ref>
      <ref id="B30-pharmaceuticals-05-00317">
        <label>30.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bernardino</surname>
              <given-names>A.M.R.</given-names>
            </name>
            <name>
              <surname>Gomes</surname>
              <given-names>A.O.</given-names>
            </name>
            <name>
              <surname>Machado</surname>
              <given-names>G.M.C.</given-names>
            </name>
            <name>
              <surname>Canto-cavalheiro</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Leon</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Amaral</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Charret</surname>
              <given-names>K.S.</given-names>
            </name>
            <name>
              <surname>Freitas</surname>
              <given-names>A.C.C.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and leishmanicidal activities of 1-(4-X-phenyl)-<italic>N'</italic>-[(4-Y-phenyl)methylene]-1<italic>H</italic>-pyrazole-4-carbohydrazides</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2006</year>
          <volume>41</volume>
          <fpage>80</fpage>
          <lpage>87</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejmech.2005.10.007</pub-id>
        </citation>
      </ref>
      <ref id="B31-pharmaceuticals-05-00317">
        <label>31.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Charret</surname>
              <given-names>K.S.</given-names>
            </name>
            <name>
              <surname>Rodrigues</surname>
              <given-names>R.F.</given-names>
            </name>
            <name>
              <surname>Gomes</surname>
              <given-names>A.O.</given-names>
            </name>
            <name>
              <surname>Bernardino</surname>
              <given-names>A.M.R.</given-names>
            </name>
            <name>
              <surname>Canto-Cavaleiro</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Leon</surname>
              <given-names>L.L.</given-names>
            </name>
            <name>
              <surname>Amaral</surname>
              <given-names>V.F.</given-names>
            </name>
          </person-group>
          <article-title>Effect of the oral treatment with pyrazole carbohydrazides derivatives in the murine infection by leishmania amazonensis</article-title>
          <source>Am. J. Trop. Med. Hyg.</source>
          <year>2009</year>
          <volume>80</volume>
          <fpage>568</fpage>
          <lpage>573</lpage>
        <pub-id pub-id-type="pmid">19346377</pub-id></citation>
      </ref>
      <ref id="B32-pharmaceuticals-05-00317">
        <label>32.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chornous</surname>
              <given-names>V.A.</given-names>
            </name>
            <name>
              <surname>Bratenko</surname>
              <given-names>M.K.</given-names>
            </name>
            <name>
              <surname>Vovk</surname>
              <given-names>M.V.</given-names>
            </name>
            <name>
              <surname>Sidorchuk</surname>
              <given-names>I.I.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and antimicrobial activity of pyrazole-4-carboxylic acid hydrazides and n-(4-pyrazoyl) hydrazones of aromatic and heteroaromatic aldehydes</article-title>
          <source>Pharm. Chem. J.</source>
          <year>2001</year>
          <volume>35</volume>
          <fpage>203</fpage>
          <lpage>205</lpage>
          <pub-id pub-id-type="doi">10.1023/A:1010432029236</pub-id>
        </citation>
      </ref>
      <ref id="B33-pharmaceuticals-05-00317">
        <label>33.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vera-DiVaio</surname>
              <given-names>M.A.F.</given-names>
            </name>
            <name>
              <surname>Freitas</surname>
              <given-names>A.C.C.</given-names>
            </name>
            <name>
              <surname>Castro</surname>
              <given-names>H.C.</given-names>
            </name>
            <name>
              <surname>Albuquerque</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Cabral</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Rodrigues</surname>
              <given-names>C.R.</given-names>
            </name>
            <name>
              <surname>Albuquerque</surname>
              <given-names>M.G.</given-names>
            </name>
            <name>
              <surname>Martins</surname>
              <given-names>R.C.A.</given-names>
            </name>
            <name>
              <surname>Henriques</surname>
              <given-names>M.G.M.O</given-names>
            </name>
            <name>
              <surname>Dias</surname>
              <given-names>L.R.S.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis, antichagasic <italic>in vitro</italic> evaluation, cytotoxicity assays, molecular modeling and SAR/QSAR studies of a 2-phenyl-3-(1-phenyl-1<italic>H</italic>-pyrazol-4-yl)-acrylic acid benzylidene-carbohydrazide series</article-title>
          <source>Bioorg. Med. Chem.</source>
          <year>2009</year>
          <volume>17</volume>
          <fpage>295</fpage>
          <lpage>302</lpage>
        <pub-id pub-id-type="doi">10.1016/j.bmc.2008.10.085</pub-id><pub-id pub-id-type="pmid">19036592</pub-id></citation>
      </ref>
      <ref id="B34-pharmaceuticals-05-00317">
        <label>34.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaushik</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Khan</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Chawla</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Kumar</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title><italic>N</italic>'-[(5-chloro-3-methyl-1-phenyl-1<italic>H</italic>-pyrazol-4-yl)methylene] 2/4-substituted hydrazides: Synthesis and anticonvulsant activity</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2010</year>
          <volume>45</volume>
          <fpage>3943</fpage>
          <lpage>3949</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejmech.2010.05.049</pub-id>
        </citation>
      </ref>
    </ref-list>
  </back>
</article>
